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Background: Depression is a prevalent disorder, associated with a high disease burden and substantial societal,
economic and personal costs. Cognitive behavioural treatment has been shown to provide adequate treatment for
depression. By offering this treatment in a blended format, in which online and face-to-face treatment are combined,
it might be possible to reduce the number of costly face-to-face sessions required to deliver the treatment protocol.
This could improve the cost-effectiveness of treatment, while maintaining clinical effects. This protocol describes the
design of a pilot study for the evaluation of the feasibility, acceptability and cost-effectiveness of blended cognitive
behavioural therapy for patients with major depressive disorder in specialized outpatient mental health care.
Methods/design: In a randomized controlled trial design, adult patients with major depressive disorder are allocated to
either blended cognitive behavioural treatment or traditional face-to-face cognitive behavioural treatment (treatment as
usual). We aim to recruit one hundred and fifty patients. Blended treatment will consist of ten face-to-face and nine online
sessions provided alternately on a weekly basis. Traditional cognitive behavioural treatment will consist of twenty
weekly sessions. Costs and effects are measured at baseline and after 10, 20 and 30 weeks. Evaluations are directed at
cost-effectiveness (with depression severity and diagnostic status as outcomes), and cost-utility (with costs per quality
adjusted life year, QALY, as outcome). Costs will encompass health care uptake costs and productivity losses due to
absence from work and lower levels of efficiency while at work. Other measures of interest are mastery, working
alliance, treatment preference at baseline, depressive cognitions, treatment satisfaction and system usability.
Discussion: The results of this pilot study will provide an initial insight into the feasibility and acceptability of blended
cognitive behavioural treatment in terms of clinical and economic outcomes (proof of concept) in routine specialized
mental health care settings, and an indication as to whether a well-powered clinical trial of blended cognitive behavioural
treatment for depression in routine practice would be advisable. This will be determined based on the perspective of
various stakeholders including patients, mental health service providers and health insurers. Strengths and limitations of
the study are discussed.
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Depression is a highly prevalent disorder [1,2]. The World
Health Organization (WHO) has predicted that by 2030
depressive disorders will have the highest disease burden
in developed countries [3]. As a result, depression is asso-
ciated with considerable costs [4-6]. These costs stem
from various sources, such as direct medical costs of
health care uptake, as well as non-medical costs associated
with patients' out-of-pocket expenses in the context of
receiving treatment. In addition, production losses related
to reduced efficiency at work and absenteeism constitute
indirect non-medical costs [4].
In addition, health care budgets are shrinking, and
mental health care resources, such as the availability of
qualified therapists, are limited [7].
It is therefore of major importance to foster the devel-
opment and implementation of depression treatments
that are both evidence-based and cost-effective [4,8]. In
addition, a much more efficient health care system is
needed to ensure that appropriate treatment can still be
delivered to those who need it.
Online treatment for depression has the potential to pro-
vide both a clinically effective [9] and an efficient approach
to the reduction of treatment costs [10]. Several meta-
analyses have shown that online treatment for depression is
effective when compared with non-intervention, both in
the short and long term, especially for cognitive behavioural
therapy (CBT) [9,11-13]. In addition, online treatment sup-
ported by a professional and face-to-face treatment have
been shown to be equally clinically effective [9,14]. How-
ever, the cost-effectiveness of online treatment is currently
less well-documented. Preliminary evidence shows that
when society is willing to invest a modest level of resources
in alleviating depressive symptoms, treatment will be cost-
effective when compared with no intervention [15] and that
online treatment can be cost-effective when compared with
face-to-face treatment [16-19].
Despite promising results, implementation and use of on-
line treatment in routine practice has been slow to get off
the ground. In the Netherlands, for example, it was recently
estimated that only 1 to 5% of patients in mental health
care are being treated online [7]. This was primarily attrib-
uted to the fact that stakeholders, such as patients and ther-
apists, seem sceptical about online treatment and the
potential costs and benefits are not yet clear to them [7].
Blended treatment could bridge the gap between stand-
alone online treatment and traditional face-to-face therapy.
This type of treatment involves a combination (blending) of
face-to-face treatment with Internet sessions into one inte-
grated treatment in such a way that it can be delivered in
routine care settings [20]. It can build on established face-
to-face treatment protocols, rather than making a full tran-
sition to a new online infrastructure. Therefore, if proven
effective, it could garner greater acceptance among variousstakeholders such as health services, therapists, and patients
compared with stand-alone online treatment.
In terms of cost-effectiveness, blended treatment could
potentially reduce the direct medical costs of treatment per
patient compared with treatment as usual, by replacing a
portion of the face-to-face sessions with more efficient on-
line sessions. By reducing the number of one-on-one ses-
sions, blended treatment also provides an opportunity for
therapists to take on more patients. This could in turn im-
prove access to treatment for those suffering from depres-
sion. Furthermore, it could contribute to lowering direct
non-medical costs of treatment, such as travel time for
patients, as they can access information and exercises any
time at home via an online platform [21].
Another possible strength of blended treatment could
be that online treatment sessions ensure structured de-
livery and monitoring of the core treatment information
and exercises, as a complement to face-to-face sessions.
In the face-to-face sessions, therapists can in turn offer
customized treatment by responding to the patient's
needs, problems or wishes in real time [22]. Furthermore,
encouraging patients to take an active role in treatment
might lead to improved self-management skills [23,24].
However, having a functional (tablet) computer with an
Internet connection and learning to work with the required
hardware, software and online environment requires both
a financial and time investment from all parties involved.
This might prove to be burdensome and more costly than
warranted by the savings made.
The number of studies that have investigated clinical
and cost-effectiveness of blended treatment for adult
depression is still limited. Preliminary results suggest
that blended treatment can be effective in diminishing
depressive symptoms [22,25-28]. Most studies focused
on evaluating clinical outcomes where online CBT is
provided in addition to care-as-usual, either by a GP in
primary care [25-27] or by mental health care providers
in primary and secondary care settings [28]. However, in
terms of cost-effectiveness, it is debatable whether this
blended approach is advisable, since treatment intensity
is increased without reducing the number of face-to-face
sessions. The uncontrolled study by Månsson et al. [22]
provides support for the proposition that face-to-face and
online sessions can be combined into a single eight to
nine-week blended CBT protocol. When offered to people
with moderate anxiety or depression in the general popu-
lation (n = 15), large within-group effect sizes were found
at both short and long-term follow-up.
The present trial will focus on blended CBT for adults
with major depressive disorder in outpatient specialized
mental health care settings. This specific target group
was chosen because in the Netherlands, this sector
accounts for more than half of health care costs related
to depression [29]. Therefore, improving efficiency and
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With the criterion of cost-effectiveness in mind, an inte-
grated approach to blended CBT was chosen, rather
than an add-on approach. Face-to-face and online ses-
sions are combined in such a way that blended CBT in-
volves less therapist time than regular face-to-face CBT.
The blended CBT protocol was developed by our pro-
ject group as part of a preliminary feasibility study.
Aims
In the present paper, we present the study protocol for a
pilot cost-effectiveness randomized controlled trial. The
primary goal of the study is to assess the probability that
blended cognitive behavioural treatment (bCBT) is more
cost-effective compared with regular face-to-face cognitive
behavioural therapy (CBTAU). Because the content of treat-
ment remains unchanged, blended cognitive behavioural
treatment is expected to maintain the clinical effectiveness
associated with face-to-face CBT [30]. This expectation is
in line with findings indicating that face-to-face CBT and
stand-alone online CBT supported by a professional appear
to be equally clinically effective [9,14].
The results of this pilot study will provide 1) an initial
insight into the feasibility and acceptability of ‘blended
treatment’ in terms of clinical and economic outcomes
(proof of concept), 2) an indication as to whether blended
treatment will add value when implemented in routine
specialized mental health care settings, and 3) a good indi-
cation as to whether an adequately powered clinical and
economic randomized controlled trial of blended treat-
ment for depression in routine practice is advisable and
feasible from the perspective of different stakeholders




The pilot study is designed as a randomized controlled
trial with two parallel groups (N = 150). Participants will
be randomized to either blended CBT (bCBT) or usual
face-to-face CBT (CBTAU). Participants in both groups
will complete assessments at baseline and at three fixed
10-week intervals after the first treatment session (Week
10, 20 and 30).
The design incorporates the ISPOR RCT-CEATask Force
recommendations for cost-effectiveness analyses along-
side clinical trials and the ISPOR Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
[31-33]. The protocol for this study has been approved
by the Medical Ethics Committee of the VU University
Medical Centre (Registration number 2014.191). Writ-
ten informed consent will be obtained from all partici-
pants. Figure 1 displays the flowchart of the study
design.Participants
Inclusion criteria
Patients aged 18 and older are eligible to participate if
they meet the criteria for a DSM-IV diagnosis of Major
Depressive Disorder (MDD). The MINI international
Neuropsychiatric Interview plus (M.I.N.I. plus), a structured
diagnostic interview performed by a trained researcher, will
be used to assess these inclusion criteria [34,35].
Exclusion criteria
Patients are excluded from the study if they a) do not
have adequate proficiency in the Dutch language, both
verbal and written, b) do not have a valid e-mail address
and a (tablet) computer with Internet access, c) suffer
from one or more of the following disorders: a psychotic
disorder, bipolar disorder and/or substance dependence, d)
are identified to be at high risk for suicide. The MINI plus
[34,35] will be used to assess whether the exclusion criteria
c and d apply. High risk of suicide is assessed through
Questions 3 to 6 of Section C of the MINI plus. Comorbid
disorders other than psychotic and bipolar disorders are
allowed, as is psychopharmacological treatment.
Excluded participants will be directed to treatment op-
tions within the participating specialized mental health care
centre. For respondents with a heightened suicide risk, the
principal investigator will inform the professional respon-
sible for treatment immediately via telephone and e-mail.
Recruitment
Patients will be recruited upon registration at the mood
disorder departments of two specialized mental health care
centres in the Netherlands. In accordance with the stand-
ard procedure within the centres, all newly registered pa-
tients first undergo an intake interview by an experienced
clinician (psychiatrist or clinical psychologist), after which
diagnosis and treatment is established and discussed with
the patient. During this conversation, patients are informed
about the present study.
After intake, the research coordinator will phone eligible
patients who are willing to participate in the study and
inform them about the trial. Interested patients will then
receive an information brochure and an informed consent
form via e-mail and will be invited to take the baseline
M.I.N.I. plus interview at the health care centre. During
this interview, a trained researcher will confirm the pri-
mary diagnosis of Major Depressive Disorder and assess
comorbidity. If patients are willing and eligible to par-
ticipate, written informed consent will be requested.
Randomization and blinding
Once the signed informed consent form has been received
and all baseline assessments have been completed, patients
will be randomly assigned to either bCBT or CBTAU.
Randomization will be performed at individual level, based
Figure 1 Flowchart of the study design.
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stratified by site by an independent researcher using a
computer generated random number table [36]. Group
allocation cannot be blinded to patients and therapists.
However, the assessors conducting the diagnostic inter-
views will be blinded to allocation, in accordance with the
CONSORT guidelines [37,38].
Interventions
Cognitive behavioural therapy (CBT) will be provided in
both treatment conditions. The CBT protocol consists
of psycho-education, behavioural activation, cognitive
therapy and relapse prevention [39]. In addition, depres-
sive symptoms will be monitored throughout the treat-
ment. CBT is one of the recommended treatments for
depression in the Netherlands, set out in the multidis-
ciplinary guidelines for depression [29]. CBT has been
extensively studied over recent decades and favourableeffects with regard to clinical outcomes have been found
consistently [30].
All participating therapists are trained in CBT and
have a minimum of two years work experience in Dutch
mental health care. Therapists work with both treatment
groups. Prior to the study, they will be trained in the
blended CBT protocol. During the trial, therapists will
attend peer group supervision meetings every other
week. The supervision meetings are guided by the head
researcher at the centre (an experienced psychologist)
and the research coordinator.
Pharmacotherapy will be offered when necessary by a
psychiatrist. The same medication regimes will be ad-
ministered for both conditions throughout the study.
Cognitive behavioural treatment-as-usual (CBTAU)
In the CBTAU condition, patients receive, on average,
twenty 45-minute sessions of face-to-face CBT over 20
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lished face-to-face CBT protocol [39] that contains the
components referred to above. Therapists are required to
include all four elements of CBT, but are free to decide
how many sessions are spent on each module.
All individual sessions should involve monitoring of
depressive symptoms, addressing the week gone by and
current issues, and discussing information and home-
work exercises for the previous week and the week to
come. Sessions will be concluded with a summary and
evaluation. Patients receive their homework exercises on
paper.
Blended cognitive behavioural treatment (bCBT)
For the bCBT group, the existing CBT protocol [39] is
divided over ten 45-minute face-to-face sessions and nine
online sessions. The treatment will be delivered over a
period of ten weeks (one face-to-face and one online
session per week). Treatment starts and ends with a
face-to-face session. The therapist follows a fixed treat-
ment protocol. The blended face-to-face sessions are
structured in a similar way to the regular face-to-face
sessions, leaving the therapist room to respond to the
individual patient’s needs in each session. During the
sessions, the patient and therapist are logged in on the
personal patient environment in the online platform.
The online platform is a secure web-based environment
(Minddistrict; www.minddistrict.com). Patients and thera-
pists access this platform with a personalized login. The
website offers information that reinforces and develops on
the content of the face-to-face sessions. A short video
fragment is included in each online session in which a
therapist explains the theory in lay terms.
In addition, patients use the website to complete
homework exercises, such as monitoring their activities,
feelings, thoughts and behaviour. Testimonials from two
fictional patients are provided to give insight in how the
exercises can be executed.
Therapists monitor their patients’ online progress and
provide feedback each week before the next face-to-face
session. The feedback messages take approximately 15
minutes to write and are sent on the online platform to
ensure secure communication.
On completion of treatment, patients can continue to
access the online treatment platform to reread informa-
tion and look up homework exercises, such as the relapse
prevention plan.
Assessments
The health-economic analyses combine clinical out-
comes (i.e., depression severity and diagnosis of major
depressive disorder) and quality adjusted life years
(QALYs) with cost estimates (both direct and indirect
costs).Data are collected at four intervals: at baseline (T0), 10
weeks after commencing treatment (T1), 20 weeks after
commencing treatment (T2) and 30 weeks after commen-
cing treatment (T3). All questionnaires are administered
online. Diagnostic interviews are administered either face-
to-face at the treatment location or via telephone, based
on the patient’s preference. Table 1 provides an overview
of the measures that are used at each time point.
Clinical outcome measures
Diagnosis of depression
The Mini-International Neuropsychiatric Interview (MINI)
[34] is a brief clinician-administered structured diagnostic
interview for assessing the presence of psychiatric disorders
as per the Diagnostic and Statistical Manual of Mental
Disorders (Fourth edition; DSM-IV) and the International
Classification of Diseases, Tenth Revision (ICD-10). The
interview has been validated in Dutch [35].
At T0, the MINI will be administered to assess past
and present MDD (including number of episodes, age of
onset, and duration of current episode) and comorbid
disorders. At T1 and T2, only Section A of the MINI
will be administered to assess the presence of MDD. At
T3, the full MINI will be administered again to assess
current MDD and comorbid disorders.
Severity of depressive symptoms
The 28-item self-report version of the Inventory of Depres-
sive Symptoms (IDS-SR) will be used to measure the sever-
ity of depressive symptoms [40]. The IDS-SR will be
administered at all time points (T0-T3). Each item has four
response categories, with scores ranging from 0 to 3. The
total score ranges from 0 to 84, with higher scores being
indicative of a higher severity of depressive symptoms. The
IDS-SR has highly acceptable psychometric properties and
has been proven to be sensitive to treatment effects in de-
pressed outpatients [41-43]. Patients with a ≥50% symptom
reduction on the IDS-SR will be deemed to be treatment
responders. Remission is defined as an IDS-SR score of 13
or less, which is indicative of no depression severity [42].
A shortened version of the IDS-SR, the 16-item Quick
Inventory of Depressive Symptomatology (QIDS-SR) [44]
is administered within both treatment conditions to moni-
tor the depressive symptom change trajectory more
closely. Patients are encouraged to complete the QIDS-SR
on a weekly basis. The questionnaire has highly acceptable
psychometric properties [44].
Measures for quality adjusted life years
Quality of life
The EQ-5D-3L [45,46] will be administered at all time
points (T0-T3) to assess quality of life. This question-
naire consists of five items and a visual analogue scale
(VAS). Each item has three response categories, ranging
Table 1 Overview of measures administered at each assessment interval
Questionnaire Aim Baseline (T0) Week 10 (T1) Week 20 (T2) Week 30 (T3)
Primary outcomes
IDS-SR Depression severity x x x x
MINI plus full Diagnostic interview x x
MINI plus; Section A x x
EQ-5D-3L Health-related QoL x x x x
SF-36 Functional impairment x x x x
TiC-P Health care utilization x x x x
Other variables of interest
General patient characteristics x
A priori treatment preference x
Mastery Scale Locus of control x x x x
WAI-SR Therapeutic alliance x
CCL-D Depressive cognitions x x x
CSQ Treatment satisfaction x
SUS (bCBT only) System usability x
bCBT: Blended Cognitive Behavioural Therapy; CCL-D: Cognition Checklist-Depression scale; CSQ: Client Satisfaction Questionnaire; EQ-5D-3L: EuroQol; IDS-SR: Inventory
of Depressive Symptomatology, Self-Report version; MINI plus: Mini International Neuropsychiatric Interview Plus; QoL: Quality of Life; SF-36: 36-item Short Form Health
Survey; SUS: System Usability Scale; TiC-P: Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness; WAI-SR: Work Alliance Inventory-Short Revised.
Kooistra et al. BMC Psychiatry 2014, 14:290 Page 6 of 11
http://www.biomedcentral.com/1471-244X/14/290from 1 (no problems) to 3 (severe problems). The items
provide insight on perceived problems in the areas of
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. On the VAS, patients can rate their
health state from 0 (worst possible health state) to 100
(best possible health state).
Based on the combination of answers on the five items,
the questionnaire differentiates between 243 distinct health
states (for example 11231), for which pre-determined
values (utility scores) have been set, anchored at 0 (death)
and 1 (good health) [46]. The utility score is then used to
compute quality-adjusted life years (QALYs). This is done
by weighing the amount of time spent in a particular health
state against its corresponding utility score [47,48].
Functional impairment
The 36-item Short Form Health Survey (SF-36) is used to
measure functional impairment and to assess health-
related quality of life [49-52] using the Brazier algorithm,
which maps utilities on 249 health states [53] which can be
extracted from six SF-36 items, namely physical function-
ing, role limitation due to physical problems, bodily pain,
general health, social functioning, role limitations due to
emotional problems, mental health and vitality. Thus, the
SF-36 offers a second way to measure QALY changes [48].
Cost calculations
The economic evaluation will be conducted from both the
health care and the societal perspective. Therefore, both
medical costs and non-medical costs (direct and indirect)
are calculated.Medical costs
The medical costs that arising from health care uptake
are assessed using Part 1 of the Trimbos/iMTA ques-
tionnaire for Costs Associated with Psychiatric Illness
(TiC-P) [54]. The questionnaire will be administered at
all time points (T0-T3). The TiC-P is the most widely
used health care service recipient interview used for eco-
nomic evaluations in the Netherlands. Part 1 consists of
23 questions on health care uptake among relevant
health care providers in the past four weeks, such as
medication taken and the number of contacts within the
mental health care settings. Patients indicate whether
they visited a health care provider and, if so, how often.
To determine the costs associated with such visits, care
consumption is multiplied by the Dutch standard cost
price (i.e. the full economic cost prices) as outlined in
the guideline for economic evaluation [55]. All costs will
be indexed for the reference year 2014.
Intervention costs
Apart from health care uptake, the costs of developing
and maintaining the online bCBT platform will be taken
into account, as well as the costs of weekly therapist
feedback in the bCBT condition.
Non-medical costs
Direct non-medical costs, or patients’ out-of-pocket ex-
penses, such as the cost of traveling to attend health ser-
vices and the costs associated with the time spent by
patients travelling, waiting and receiving treatment, are
determined in accordance with the standard cost prices
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evaluation [55].
Indirect non-medical costs, stemming from productiv-
ity losses due to absenteeism and lower efficiency levels
while at work, are assessed with the second part of the
Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness (TiC-P) [54], which evaluates product-
ivity losses in the past four weeks. It will be administered
at all time points (T0-T3). The questionnaire consists of
12 questions that focus on the number of days absent
from work and the number of days with reduced effi-
ciency due to feeling ill. The costs of productivity losses
will be based on the gender and age specific friction
costs, as outlined in the Dutch guideline for costing [55].
Other variables of interest
General patient characteristics
Information on general demographic variables such as
age, gender, marital status, income and educational level
and data on patients’ professional and personal computer
use will be collected at baseline.
Treatment preference
In order to determine whether this influences treatment
outcomes, patients are asked what their treatment pref-
erence would have been, before they are informed about
their actual treatment allocation. The possible answers
are preference for bCBT or a preference for CBTAU.
Whether or not the preference matches the treatment
allocation will be taken into account.
Mastery
The 5-item version of the Mastery Scale [56] is adminis-
tered at all time points (T0-T3) to assess changes in
locus of control. Item scores range from 1 to 5, resulting
in total scores ranging from 5 to 25, with higher scores
being indicative of a higher degree of perceived control.
The scale has good psychometric properties [56].
Work alliance
The Revised Short Version of the Work Alliance Inventory
(WAI-SR) [57,58] is administered to both patients and
therapists in order to determine the quality of the thera-
peutic alliance at T1. Item scores range from 1 to 5. The
total score ranges from 12 to 60, with higher scores
reflecting a better alliance between therapist and patient.
The questionnaire has highly acceptable psychometric
properties [58].
Depressive cognitions
The 14-item depression scale of the Cognition Checklist
[59] will be administered at all time points (T0-T3) to
assess the frequency of automatic thoughts relevant to
depression. The items assess the frequency with which athought typically occurs. Item scores range from 0 to 4.
Total scores range from 0 to 56 with higher scores being
indicative of more frequent negative depressive cogni-
tions. The convergent and discriminant validity of the
subscale has been found to be high [60].
Treatment evaluation
The 8-item Client Satisfaction Questionnaire-8 (CSQ-8)
[61] will be administered at T3 to determine general satis-
faction with treatment. High internal consistency has been
reported [62]. In addition, the 10-item System Usability
Scale (SUS) [63] will be administered to participants ran-
domized to bCBT at T2 in order to evaluate the online
blended treatment platform. The questionnaire has been
found to be reliable [64].
Process data
Data for process analyses will be obtained from the admin-
istration offices of participating mental health care institu-
tions and through usage statistics on the online platform.
In addition, we will perform qualitative interviews with a
random selection of ten patients per treatment group after
Week 30. The interviews will focus on the feasibility and
usability of the CBT treatment provided.
In the process analyses, we will also include the aspects
that serve as input for the study flow chart in accordance
with the CONSORT guidelines [36,38], such as exclusions,
as well as study and treatment withdrawal rates for each
group, including reasons. In addition, we will assess:
– The extent to which other treatments were provided
in parallel with bCBT or CBTAU, such as
pharmacotherapy, and the nature of this treatment.
– The total number of online sessions and/or face-to-
face contacts and cancellations (amount of therapy
received);
– Time investment by both the patient and the
therapist. In the bCBT group, time investment can
be calculated based on the number of face-to-face
contacts and the amount of time spent working on
the online platform. In the CBTAU group, time




Given the nature of our pilot study, we chose to conduct a
cost-effectiveness study, in which we focus on the prob-
ability of cost-effectiveness of bCBT in comparison with
CBTAU for various ‘willingness to pay’ ceilings, i.e., the
cost-effectiveness acceptability curve (CEAC; Fenwick
et al. 2001). The probabilistic assessment does not entail
hypothesis testing. Instead, the outcomes will be presented
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in terms of cost-effectiveness [18].
Through a simulation study, we determined the impact
of various sample sizes on the stability of the CEAC. Using
realistic fixed estimates of the mean and standard devi-
ation of effects and costs at population level (based on
Hakkaart-van Roijen et al., 2006), we simulated a large
number of trials in which we systematically varied sample
sizes between n = 10 to n = 500 per group (n = 10, 25, 50,
75, 150, 500). As expected, the stability of the CEAC
improved with increasing sample size. Below n ≤50, prob-
ability estimates were highly unstable. At a sample size
of n = 75 per group, however, we found probability esti-
mates to converge to acceptable 75% percentile ranges
within the relevant range of willingness to pay ceilings.
Therefore, for this study, we settled for a sample size of
N = 150 (n = 75 per group).
Statistical analyses
Primary analyses
A cost-effectiveness analysis (CEA) and cost-utility ana-
lysis (CUA) will be conducted from both the health care
perspective and the societal perspective. Therefore, we will
take direct medical costs, direct non-medical costs and
indirect medical costs into account. In addition, a budget
impact analysis (BIA) will be based on a health-economic
modelling study based on Mauskopf ’s recommendations
[32]. Based on the BIA, expected costs to the public purse,
the health care insurer and the service-provider will be
estimated.
Cost-effectiveness and cost-utility analyses
The cost-effectiveness analysis (CEA) will be based on
treatment response. Analyses will be conducted for both
treatment response, defined as a 50% pre-post reduction
of IDS-SR depressive symptoms [40,42], assessed as the
DSM-IV depression status at 30 weeks, as measured by
the MINI plus interview [35].
The cost-utility analysis (CUA) will be conducted
using quality adjusted life years (QALYs) as a generic
measurement of health gains, based on EQ-5D [45,46]
and SF-36 data [49,50,53].
In order to obtain the costs per treatment responder
and the costs per QALY gained, the incremental cost-
effectiveness ratio (ICER) will be computed using the
bootstrap method. The simulated ICERs will then be pro-
jected onto the cost-effectiveness plane and presented as
acceptability curves.
For decision-making purposes, the ICER acceptability
curve will be plotted using various willingness-to-pay
(WTP) ceilings, which supports analysis as to whether
the blended intervention offers good value for money,
compared with CBT treatment as usual. One-way sensi-
tivity analyses directed at uncertainty in the main costdrivers will be performed to assess the robustness of our
findings across a range of likely values for those parameters.
Budget impact analysis
To assess the impact of blended CBT for depression
compared with CBT as usual on health care budgets, a
budget impact analysis (BIA) will be conducted as out-
lined by Mauskopf et al. [32]. The BIA will assess the
impact on 1) wider society (including productivity
losses), 2) the public purse, and 3) health insurers and
health care service providers. When taking the public
purse and health insurance companies into account, the
focus will be restricted to direct medical costs. For each
angle, we assess costs when 10%, 20%, 30% and 100% of
the target group receive bCBT. These scenarios will be
compared with the baseline scenario, reflecting current
care, where 0% of the target group is offered bCBT.
Regarding the costs to wider society, we will assess the
costs of offering the health care interventions, as well as
the interventions offered in routine specialized mental
health care for this particular target group, patients’ out
of pocket expenses, and costs arising from productivity
losses.
The BIA will be conducted using a health economic
(Markov cohort) simulation model, called DepMod [16].
The model is based on the epidemiology of depressive dis-
order as obtained from the population-based NEMESIS
psychiatric cohort study [65]. DepMod compares two
health care systems: care-as-usual for depressive disorder
and the alternative health care scenario with blended cogni-
tive behavioural treatment. Costs and effects will be mod-
elled for the short term (1 year) and longer term (5 years),
at national level, as well as those incurred by the health care
provider and health insurance company. Long-term costs
and effects will be discounted in accordance with the Dutch
guidelines [55]. DepMod involves extensive sensitivity ana-
lyses that cover cost, effect and discounting parameters
simultaneously [66].
Explorative analyses
The analyses will be conducted in accordance with the
intention to treat (ITT) principle. Missing data will be
imputed using state of the art imputation methods, a reli-
able method for handling missing values [35]. In addition,
per protocol analyses will be conducted; if equal clinical
effects are found, such analyses are more conservative than
ITT [67].
Outcomes for continuous variables, such as severity of
depressive symptoms and mastery, at T1, T2 and T3
(Week 10, 20, and 30) are estimated for descriptive pur-
poses through mixed-model analyses (MM), with partici-
pants as random effects, and time (T1-T3), group
(bCBT vs. CBTAU) and time x group as fixed effects,
with baseline scores as a single covariate. To assess the
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Cohen’s d effect sizes [68] for each time point are calcu-
lated by dividing MM parameter estimates of fixed effects
at each post-treatment assessment by the pooled standard
deviation of outcome measurements at baseline (T0).
Effect sizes under 0.2 are deemed to be small, 0.5 are
deemed moderate and 0.8 are deemed to be large [68].
Discussion
Major Depressive disorder is a highly prevalent disorder,
with a major impact on personal, professional and family
life and is associated with considerable medical and non-
medical costs. In order to ensure the availability of afford-
able evidence-based treatments in the future, investing in
the development of cost-effective treatments is warranted.
This is especially relevant in specialized mental health
care, as treatment in this sector tends to be intensive and
of a long duration.
Blended care may offer a way to improve the cost-
effectiveness of depression treatment. This type of treat-
ment combines elements of online and face-to-face
treatment, with the goal of diminishing the number of
face-to-face sessions needed to deliver the treatment
protocol.
Strengths and weaknesses
In the proposed study, integrated blended cognitive be-
havioural treatment will be compared with face-to-face
cognitive behavioural treatment for major depression. To
the best of our knowledge, this is one of the first studies
to evaluate this type of blended treatment in an outpatient
specialized mental health care setting. Therefore, the trial is
designed as a cost-effectiveness study to assess the probabil-
ity that blended CBT is cost-effective in comparison with
face-to-face CBT in the short term (30 weeks) by way of
proof-of-concept. The results of the study provide informa-
tion on the possible strengths and benefits of blended CBT
and will support decision-making on whether an adequately
powered clinical and economic randomized controlled trial
of blended treatment for depression in routine practice is
advisable and feasible. By carrying out budget impact ana-
lyses, we aim to inform stakeholders from various perspec-
tives, including patients, mental health service providers
and health insurers.
In order to facilitate the decision-making process, the
study is designed to closely adhere to established proce-
dures in routine practice in outpatient specialized men-
tal health care. This is reflected in the decision to deliver
blended CBT over a ten-week period, while adhering to
the usual time frame of 20 weeks for the face-to-face
CBT. Two factors explain this choice in relation to
blended CBT. First, providing online and face-to-face
sessions within the same week is common practice in
the context of guided online treatment. Second, a recentmeta-analysis by Cuijpers et al. [69] showed that intensi-
fying face-to-face treatment from one to two sessions a
week might be beneficial in terms of clinical results, with
an increase in effect size of g = 0.45. In the proposed
study, the reason not to match the intensity of treat-
ment as usual is that this would deviate from current
practice, therefore undermining the goal of the pro-
posed study. As a result, any clinical results will be
harder to attribute to the blended intervention. How-
ever, the aim of this pilot study is to gain insight into
the implementation value of blended CBT, rather than
clinical effectiveness.
In summary, blended cognitive behavioural treatment
(CBT) for major depression might be more cost-effective
than face-to-face CBT as usual, while maintaining clin-
ical effects. The proposed study is designed to contrib-
ute to the body of knowledge on the possible value of
blended treatment for depression when applied in out-
patient specialized mental health care. It aims to under-
pin future decisions on whether further research on
blended treatment for depression in routine practice is
advisable and feasible.
Trial status
The trial is in the on-going recruitment phase.
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